Researchers at Stanford University are launching a new study to see whether Pfizer's anti-viral drug Paxlovid, which is approved to treat COVID-19, might also be an effective cure for so-called 'long COVID' that causes suffering in patients long after their initial SARS-CoV2 infection.
are launching a new study to see whether Pfizer's anti-viral drug Paxlovid, which is approved to treat COVID-19, might also be an effective cure for so-called "long COVID" that causes suffering in patients long after their initial SARS-CoV2 infection.
"Fatigue, cognitive issues, shortness of breath, the list really goes on," said Dr. Linda Geng, who is Co-Director of Stanford's Post-COVID clinic. "Right now we don't have known biomarkers, meaning we can't do a blood test that says this is long COVID and now we have treated it so that signal goes away. Right now and perhaps the most important thing is that we go by patients' reports, so their own report of their symptoms, their own call and judgment of the severity of their symptoms, and how much it has impacted their daily lives. So for our study, that's what we will be measuring.
"I had one of the first confirmed cases of COVID in the country in early March 2020," said Güthe. She says after she got better, though, some symptoms didn't go away, "I had what I call a relapsing remitting case of long COVID They came in went for several months lasted about up to a year. "
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Covid-19 rebound may be more common in people who take Paxlovid, early study suggests | CNNCases of Covid-19 rebound following treatment with the antiviral medication Paxlovid -- where infections rev back up again after people complete their five-day course of the medication -- appear to be at least twice as common as doctors previously knew, a new study suggests. Covid-19 rebound also seems to be more common in people who take Paxlovid compared with those who don't take the antiviral, although it can happen in either circumstance.
Consulte Mais informação »
Opinion | Meet the Post-Covid China, Same as the Pre-Covid ChinaFrom WSJopinion: When zero-Covid finally ends and travel and business resume, will the world remember the pandemic’s lesson about the Chinese Communist Party, asks Anastasia Lin
Consulte Mais informação »
New Pfizer-BioNTech Covid Vaccine Is More Effective Than The Original, Study ShowsAn estimated 68% of Americans are fully vaccinated.
Consulte Mais informação »
Pfizer, Moderna researching rare side effect linked to COVID vaccinesWith a triple-threat virus sweeping across the country, pharmaceutical companies have launched their own clinical trials on COVID vaccines in young adults and t
Consulte Mais informação »
Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.
Consulte Mais informação »
Pfizer COVID booster spurs immune response to new omicron subtypesPfizer said Friday that its updated COVID-19 booster may offer some protection against newly emerging omicron mutants even though it’s not an exact match.
Consulte Mais informação »